OneSource Specialty Pharma Limited reported a 26% YoY decrease in revenue to ₹2,903 million for Q3FY26 due to delayed semaglutide approvals in Canada. EBITDA also declined significantly to ₹173 million. The company reaffirmed its FY28 guidance of $400 million in organic revenue and $500 million including recently proposed acquisitions.
Q3FY26 Financial Performance
OneSource Specialty Pharma Limited announced its consolidated financial results for the quarter ended December 31, 2025 (Q3FY26). Key highlights from the announcement include:
Revenues for Q3FY26 stood at ₹2,903 million, a decrease of 26% YoY, primarily due to delayed semaglutide approvals in Canada.
EBITDA was reported at ₹173 million, down 88% YoY.
The adjusted PAT was ₹(472) million, with an adjusted EPS of (₹4.1).
FY28 Guidance Reaffirmed
The company reaffirmed its FY28 guidance, including:
$400 million in organic revenue and $500 million including recently proposed acquisition.
Management Commentary
Mr. Neeraj Sharma, CEO & MD, commented that the quarter was subdued due to customer approval delays in Canada. He added that the underlying demand remains intact and the company continues to see strong interest in its biologics segment.
Source: BSE
